Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
7.30
Ask:
7.50
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Directorate Change

14 Feb 2018 07:00

RNS Number : 8078E
Feedback PLC
14 February 2018
 

This announcement contains inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 (MAR).

14 February 2018

Feedback plc

 

("Feedback" or the "Company")

 

Directorate change

Appointment of new Chief Executive Officer to drive growth strategy

Cambridge, UK - 14 February 2018: Feedback plc ("Feedback" or the "Company") (AIM: FDBK), the specialist medical imaging technology company, announces that it has appointed David Crabb as Chief Executive Officer and a director of Feedback with immediate effect. This appointment will underpin the execution of the Company's growth strategy following the first CE marked release of TexRAD®; the Company's patented quantitative image texture analysis technology for diagnostic radiological scans.

Mr Crabb brings 20 years of experience as an effective business leader to Feedback. Most recently he was Chief Executive Officer of Cambridge Online Systems, a major software company providing services to UK and international customers, which was acquired by the global IT group Columbus in December 2016. Under Mr Crabb's management in 2011, Cambridge Online Systems delivered strong growth from a loss-making organisation to one with top-quartile financial results and was voted as one of the "Sunday Times Top 100 Companies to work for" in two consecutive years. Previously, Mr Crabb held director-level roles in medium-sized technology and outsourced solutions companies with revenues from £50 million to over £1 billion, responsible for business optimisation, sales and marketing and workforce leadership.

Dr Alastair Riddell, Chairman of Feedback plc, said: "Since the acquisition of Cambridge Computed Imaging Ltd and TexRAD Limited in 2014, Feedback plc has developed a strong reputation in the field of medical imaging and is privileged to be working with over 40 of the world's leading research institutions. We recognise that a small, multi-disciplinary team has its limitations, which resulted in some operational delays over the past 12 months, so I am delighted that Feedback has attracted a highly experienced executive to complement the strong technical and regulatory expertise within the Company. Under David's leadership, we are well-positioned to leverage our pioneering technology to create evidence-based imaging software, arming clinicians with innovative tools to improve patient outcomes."

David Crabb, Chief Executive Officer of Feedback plc, commented: "I am impressed with the platform technologies and domain expertise at Feedback. The medical imaging and diagnostics market is a dynamic, fast-paced environment where disruptive technologies are very much needed. The opportunity is not without its challenges, as with all pioneering development, but as a small, ambitious company which has experienced both acquisition and organic growth, there is significant opportunity to optimise and expand Feedback's operations. Our long-term vision is to lead global innovation in quantitative medical imaging analysis - I believe we have strong foundations to position ourselves at the forefront of this important field and I am looking forward to refining our strategy over the coming months."

Regulatory Disclosures

In accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies, David James Crabb, aged 50 is, or has been within the last five years, a director or partner in the following companies and partnerships: 

Current directorships and partnerships

Past directorships and partnerships held within the last five years

David Crabb Consulting Limited

Cambridge Online Systems Limited

 

There is no other information required to be disclosed under the AIM Rules for Companies.

Notes to editors

About Feedback plc

Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.

 

For further information, please contact:

 Feedback plc

David Crabb, Chief Executive Officer

Lara Mott, Investor Relations

 

Tel: 01954 718072

IR@fbk.com

Allenby Capital Limited (Nominated Adviser and Joint Broker)

David Worlidge / Asha Chotai

Tel: 020 3328 5656

Northland Capital Partners Ltd (Joint Broker)

David Hignell / John Howes

Tel: 020 3861 6625

Peterhouse Corporate Finance Ltd (Joint Broker)

Lucy Williams / Duncan Vasey

Tel: 020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATJMJTMBABTBP
Date   Source Headline
22nd Apr 20262:10 pmRNSGrant of Options and PDMR dealing
20th Apr 20267:00 amRNSNHS Progress and Business Update
17th Feb 202610:43 amRNSCorrection: Half-year Report
17th Feb 20267:00 amRNSHalf-year Report
2nd Feb 20267:00 amRNSNotice of Results & Retail Investor Presentation
5th Jan 20264:13 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
18th Dec 20257:00 amRNSTrading Update
20th Oct 20257:00 amRNSDirectorate Change
13th Oct 20254:04 pmRNSResult of AGM
18th Sep 20251:07 pmRNSNotice of AGM
17th Sep 20257:00 amRNSFinal Results
8th Sep 20257:00 amRNSNotice of Results & Retail Investor Presentation
10th Jul 20257:00 amRNSGrant of Options and PDMR dealing
12th Jun 20257:00 amRNS-RNeighbourhood Health Service Simulation
7th May 202510:44 amRNSHolding(s) in Company
6th May 20251:01 pmRNSHolding(s) in Company
28th Apr 20257:00 amRNSTrading Update
25th Feb 20257:00 amRNSHalf-year Report
11th Feb 20257:00 amRNSNotice of Results & Investor Presentation
14th Jan 20257:00 amRNSSurrender and grant of options and PDMR dealings
18th Dec 20243:07 pmRNSHolding(s) in Company
18th Dec 20247:00 amRNSHalf Year Trading Update
9th Dec 202410:56 amRNSHolding(s) in Company
9th Dec 202410:48 amRNSHolding(s) in Company
4th Dec 20247:00 amRNSHolding(s) in Company
3rd Dec 202412:33 pmRNSHolding(s) in Company
3rd Dec 202412:18 pmRNSHolding(s) in Company
2nd Dec 202411:53 amRNSHolding(s) in Company
2nd Dec 202411:46 amRNSHolding(s) in Company
2nd Dec 20247:00 amRNSDirector/PDMR Shareholding
29th Nov 20243:36 pmRNSHolding(s) in Company
29th Nov 20243:33 pmRNSHolding(s) in Company
28th Nov 20242:35 pmRNSResult of AGM & Commercial Update
6th Nov 20247:00 amRNSResult of WRAP Retail Offer
4th Nov 20243:46 pmRNSSuccessful Fundraising upscaled to c. £5.57m
4th Nov 20247:02 amRNSWRAP Retail Offer for up to £1 million
4th Nov 20247:01 amRNSProposed Fundraise & Share Capital Reorganisation
4th Nov 20247:00 amRNSFinal Results
16th Oct 20247:00 amRNSElective Recovery Fund funding mechanism
19th Sep 20247:00 amRNSCollaboration Agreement
2nd Sep 20247:00 amRNSFurther funding to extend NHS Trust pathways
10th Jul 20247:00 amRNSVertex In Healthcare Collaboration
1st Jul 20247:00 amRNSCDC Contract Awarded by Queen Victoria Hospital
28th Jun 20247:00 amRNSChange of Name of Nominated Adviser and Broker
22nd May 20247:00 amRNSTrading Update
25th Mar 20247:00 amRNSNew tuberculosis partnership in India

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.